PRESENT STATUS OF COMBINED ATTENUATED LIVE VIRUS VACCINE

Development of an Attenuated Live Virus Vaccine against Sheep Pox

Development of a New Live Attenuated Mumps Virus Vaccine in Human Deploid Cells

Small-particle aerosolization of live attenuated influenza vaccine virus.

To the Editor—In their recent study, Bischoff et al [1] exposed subjects to a small-particle aerosol of commercially available live attenuated influenza vaccine (LAIV; MedImmune LLC, Gai-thersburg, MD). LAIV was used as a proxy for wild-type influenza to evaluate the protection provided by N95 respirators, surgical masks, and eye protection. Although the study addresses the important question o...

Caution about Newcastle disease virus-based live attenuated vaccine.

In several recent papers, two published last year in the Journal of Virology by DiNapoli et al. (3) and Ge et al. (4), an earlier study by Martinez-Sobrido et al. in 2006 (6), and a review by Bukreyev et al. in 2006 (1), Newcastle disease virus (NDV) is proposed as a potential vector in the development of a novel bior multivalent vaccine. We question whether those studies satisfactorily address...

Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

Three novel recombinant dengue type 3 (DEN3) virus vaccine candidates have been generated from a DEN3 virus isolated from a mild outbreak of dengue fever in the Sleman area of central Java in Indonesia in 1978. Antigenic chimeric viruses were prepared by replacing the membrane precursor and envelope (ME) proteins of recombinant DEN4 (rDEN4) virus with those from DEN3 Sleman/78 in the presence (...